BiotechTube

SHR-1701 + Gemcitabine + Cisplatin + Albumin Paclitaxel

Phase 1UNKNOWN
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Nasopharyngeal Carcinoma

Conditions

Nasopharyngeal Carcinoma

Trial Timeline

Mar 27, 2020 → Dec 15, 2022

NCT ID
NCT04282070

About SHR-1701 + Gemcitabine + Cisplatin + Albumin Paclitaxel

SHR-1701 + Gemcitabine + Cisplatin + Albumin Paclitaxel is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Nasopharyngeal Carcinoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT04282070. Target conditions include Nasopharyngeal Carcinoma.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04282070Phase 1UNKNOWN

Competing Products

20 competing products in Nasopharyngeal Carcinoma

See all competitors
ProductCompanyStageHype Score
Nanatinostat + Valganciclovir + PembrolizumabViracta TherapeuticsPhase 1
25
Cisplatin 2 + Docetaxel + Cisplatin 1Sun PharmaceuticalPhase 2
52
CisplatinSun PharmaceuticalPhase 3
77
Cisplatin 1 + Cisplatin 2 + Docetaxel + XelodaSun PharmaceuticalPhase 3
77
5-fu + Lobaplatin + Placebo + leucogenSun PharmaceuticalPhase 3
77
CapecitabineSun PharmaceuticalPhase 3
77
Amifostine every-other-day regimen + Amifostine everyday regimenSun PharmaceuticalPhase 2
52
Nedaplatin + CisplatinSun PharmaceuticalPhase 3
77
PD-1 blocking antibody + Gemcitabine + Cisplatin (80 mg/m2) + Cisplatin (100 mg/m2) + CapecitabineSun PharmaceuticalPhase 3
77
QL1706 + Gemcitabine + CisplatinSun PharmaceuticalPhase 3
77
The combination treatment of anlotinib, penpulimab and capecitabine.Sun PharmaceuticalPhase 2
52
docetaxel, nedaplatin, and capecitabine + nedaplatin + docetaxel, cisplatin, and fluorouracil + cisplatin + docetaxel, cisplatin, and capecitabine + docetaxel, nedaplatin, and fluorouracilSun PharmaceuticalPhase 3
77
Pemetrexed (Alimta)Eli LillyPhase 2
52
Camrelizumab + Placebos + Gemcitabine + CisplatinJiangsu Hengrui MedicinePhase 3
77
Famitinib + CisplatinJiangsu Hengrui MedicinePhase 1
33
SHR-1210 + Gemcitabine + cis-platinumJiangsu Hengrui MedicinePhase 1
33
FamitinibJiangsu Hengrui MedicinePhase 2
52
ApatinibJiangsu Hengrui MedicinePhase 2
52
SHR-1210Jiangsu Hengrui MedicinePhase 2
52
SHR-1701 + FamitinibJiangsu Hengrui MedicinePhase 1/2
41

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85